In 2015, the European Union approved the combination of dabrafenib and the MEK inhibitor trametinib ("D + T" regimen) for the treatment of adult patients with unresectable or metastatic melanoma positive for the BRAF V600 E/K mutation.83 Here, MAP2K7 is linked to metastatic melanoma.